Paul Markus Müller

Paul Markus Müller

Auto-generated profile, based on publicly available information

Paul Markus Müller

Institute of Biochemistry, Freie Universität Berlin, Berlin, Germany

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 March 2020 in Nature Cell Biology
Verified
Journal Article
Closed access
PDF file
PMPaul M. Müller
Paul M. Müller
JRJuliane Rademacher
Juliane Rademacher
RBRichard D. Bagshaw
Richard D. Bagshaw
CWCelina Wortmann
Celina Wortmann
CBCarolin Barth
Carolin Barth
OROliver Rocks
Oliver Rocks

7 October 2016 in Nature Communications
Verified
Journal Article
Open access
PDF file
RERebecca L. Eccles
Rebecca L. Eccles
MCMaciej T. Czajkowski
Maciej T. Czajkowski
CBCarolin Barth
Carolin Barth
PMPaul Markus Müller
Paul Markus Müller
EMErik McShane
Erik McShane
OROliver Rocks
Oliver Rocks
Protein kinase A is a key mediator of cAMP signalling downstream of G-protein-coupled receptors, a signalling pathway conserved in all eukaryotes. cAMP binding to the regulatory subunits (PKAR) relieves their inhibition of the catalytic subunits (PKAC). Here we report that ARHGAP36 combines two distinct inhibitory mechanisms to antagonise PKA signalling. First, it blocks PKAC activity via a pseudosubstrate motif, akin to the mechanism employed by the protein kinase inhibitor proteins. Second, it targets PKAC for rapid ubiquitin-mediated lysosomal degradation, a pathway usually reserved for transmembrane receptors. ARHGAP36 thus dampens the sensitivity of cells to cAMP. We show that PKA inhibition by ARHGAP36 promotes derepression of the Hedgehog signalling pathway, thereby providing a simple rationale for the upregulation of ARHGAP36 in medulloblastoma. Our work reveals a new layer of PKA regulation that may play an important role in development and disease.

1 October 2012 in Free Radical Biology and Medicine
Verified
Journal Article
Closed access
PMPaul Markus Müller
Paul Markus Müller
RGRobert Gnügge
Robert Gnügge
SDSandeep Dhayade
Sandeep Dhayade
MTMartin Thunemann
Martin Thunemann
PKPeter Krippeit-Drews
Peter Krippeit-Drews
RFRobert Feil
Robert Feil

26 January 2018 in PLOS ONE
Verified
Journal Article
Open access
PDF file
KSKatharina Schrade
Katharina Schrade
JTJessica Tröger
Jessica Tröger
AEAdeeb Eldahshan
Adeeb Eldahshan
KZKerstin Zühlke
Kerstin Zühlke
KAKamal R Abdul Azeez
Kamal R Abdul Azeez
Enno KlussmannEnno Klussmann
Enno Klussmann
Stimulation of renal collecting duct principal cells with antidiuretic hormone (arginine-vasopressin, AVP) results in inhibition of the small GTPase RhoA and the enrichment of the water channel aquaporin-2 (AQP2) in the plasma membrane. The membrane insertion facilitates water reabsorption from primary urine and fine-tuning of body water homeostasis. Rho guanine nucleotide exchange factors (GEFs) interact with RhoA, catalyze the exchange of GDP for GTP and thereby activate the GTPase. However, GEFs involved in the control of AQP2 in renal principal cells are unknown. The A-kinase anchoring protein, AKAP-Lbc, possesses GEF activity, specifically activates RhoA, and is expressed in primary renal inner medullary collecting duct principal (IMCD) cells. Through screening of 18,431 small molecules and synthesis of a focused library around one of the hits, we identified an inhibitor of the interaction of AKAP-Lbc and RhoA. This molecule, Scaff10-8, bound to RhoA, inhibited the AKAP-Lbc-mediated RhoA activation but did not interfere with RhoA activation through other GEFs or activities of other members of the Rho family of small GTPases, Rac1 and Cdc42. Scaff10-8 promoted the redistribution of AQP2 from intracellular vesicles to the periphery of IMCD cells. Thus, our data demonstrate an involvement of AKAP-Lbc-mediated RhoA activation in the control of AQP2 trafficking.

20 June 2016 in Oncotarget
Verified
Journal Article
Open access
MBMichael S. Becker
Michael S. Becker
PMPaul M. Müller
Paul M. Müller
JBJörg Bajorat
Jörg Bajorat
ASAnne Schroeder
Anne Schroeder
MGMarco Giaisi
Marco Giaisi
MLMin Li-Weber
Min Li-Weber
The anticancer phytochemical rocaglamide inhibits Rho GTPase activity and cancer cell migration

29 March 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
RGRaluca Groza
Raluca Groza
KSKita Valerie Schmidt
Kita Valerie Schmidt
PMPaul Markus Müller
Paul Markus Müller
PRPaolo Ronchi
Paolo Ronchi
CSClaire Schlack-Leigers
Claire Schlack-Leigers
HEHelge Ewers
Helge Ewers
Several bacterial toxins and viruses can deform membranes through multivalent binding to lipids for clathrin-independent endocytosis. However, it remains unclear, how membrane deformation and endocytic internalization are mechanistically linked. Here we show that many lipid-binding virions induce membrane deformation and clathrin-independent endocytosis, suggesting a common mechanism based on multivalent lipid binding by globular particles. We create a synthetic cellular system consisting of a lipid-anchored receptor in the form of GPI-anchored anti-GFP nanobodies and a multivalent globular binder exposing 180 regularly-spaced GFP molecules on its surface. We show that these globular, 40 nm diameter, particles bind to cells expressing the receptor, deform the plasma membrane upon adhesion and become endocytosed in a clathrin-independent manner. We explore the role of the membrane adhesion energy in endocytosis by using receptors with affinities varying over 7 orders of magnitude. Using this system, we find that once a threshold in adhesion energy is overcome to allow for membrane deformation, endocytosis occurs reliably. Multivalent, binding-induced membrane deformation by globular binders is thus sufficient for internalization to occur and we suggest it is the common, purely biophysical mechanism for lipid-binding mediated endocytosis of toxins and pathogens.